Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

ATXS

Phase 1a

STAR-0310

Atopic dermatitis

Q3 2025

03/04/24- IND submission by YE 2024. Present preclin profile at a scientific meeting in 2024. Presentation at EAACI '24. 12/10/24- Received IND clearance. 1/23/25- Initiated Ph1a trial. Early proof-of-concept results in Q3 2025.

Data readout

DVAX

Phase 1/2

Z-1018 (adjuvanted w/ CpG 1018)

Shingles (adults aged 50 years and older)

Q3 2025

6/27/24- First participant dosed. 2/20/25- Topline data in Q3 2025.

Data readout

SXTP

Phase 2a

Tafenoquine

Babesiosis

September 2025

6/11/24- Granted FDA ODD. 6/27/24- First patient enrolled. 7/9/24- Received IRB approval. 7/19/24- CTA signed and 3 sites fully initiated. Enrollment ongoing w/ interim data in 9/2025. 1/28/25- IRB approval of Ph2 study. Enrollment to commence in Q3 2025.

Initiation

ATYR

Phase 3

Efzofitimod

Pulmonary sarcoidosis

Q3 2025

EFZO-FIT™ study. Topline data in Q3 2025. Posters at ATS 2025 on May 16 – 21, 2025.

Data readout

RPTX

Phase 1

RP-3467 +/- olaparib

Solid tumors

Q3 2025

POLAR study. 10/14/24- First patient dosed. 3/3/25- Topline data in Q3 2025.

Data readout

SCYX

Phase 1

SCY-247

Candida auris and Mucorales infection

Q3 2025

11/6/24- Preclinical studies presented at a medical conference. Initiate trial in Q4 2024. 12/18/24- Initiated dosing. 3/12/25- Report results in Q3 2025.

Data readout

PRAX

Phase 3

Ulixacaltamide (PRAX-944) (T-type calcium channel blocker)

ET (Essential Tremor)

Q3 2025

Essential1 & Essential3 trials: 8/9/23- Initiated Essential3. 10/3/23- Submit NDA in 2025. Planned Interim analysis for study 1 in Q1 '25. 2/28/25- IDMC recommends the study to be stopped for futility. Decided to continue study w/ topline data in Q3 2025.

Data readout

ASMB

Phase 1a

ABI-6250

Hepatitis Delta virus (HDV)

Q3 2025

2/26/25- First patient dosed. 3/20/25- Healthy participants data in Q3 2025.

Data readout

FDMT

Phase 2

4D-150

Diabetic Macular Edema (DME)

Q3 2025

SPECTRA trial. 02/23- IND cleared. 4/12/24 Enrollment & dosing complete. 1/10/25- Interim data reported. 2/28/25- 52wk interim data update at a scientific conference in Q3 2025. Per FDA, may proceed to Ph3 trial.

Data Readout

ZBIO

Phase 2

Obexelimab (CD19xFcyRIIb)

Relapsing Multiple Sclerosis (RMS)

Q3 2025

MoonStone trial. 11/12/24- Trial initiated. 12-wk primary endpoint results in Q3 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20